Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Our AI ranks Cerus Corp outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Cerus Corp is a small-cap company with a market capitalization of $439M. It ranks number 49 by market capitalization among the 60 Surgical & Medical Instruments & Apparatus issuers in our coverage with a current forecast.
For CERS, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 29.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 25.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CERS included.
Follow CERS free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Surgical & Medical Instruments & Apparatus peers listed below that report each metric.
| Metric | CERS | Rank |
|---|---|---|
| Market Cap | $439M | 49/60 |
| P/B Ratio | 6.27x | 20/55 |
| EPS | $-0.06 | – |
| Book Value/Share | $0.35 | – |
| FCF/Share | $-0.01 | – |
| Metric | CERS | Rank |
|---|---|---|
| ROE | -9.7% | 22/41 |
| ROA | -3.3% | 22/44 |
| ROIC | -1.4% | 27/53 |
| Operating Margin | -0.3% | 27/54 |
| Net Margin | -1.2% | 21/43 |
| EBT Margin | -1.2% | 29/54 |
| Tax Rate | -6.0% | – |
| Metric | CERS | Rank |
|---|---|---|
| Current Ratio | 1.83x | 49/59 |
| Quick Ratio | 1.07x | 49/55 |
| D/E Ratio | 1.92x | 10/56 |
| Financial Leverage | 2.93x | 12/54 |
| Interest Coverage | -0.1x | 26/48 |
| Working Capital | $72M | 53/59 |
| Metric | CERS | Rank |
|---|---|---|
| Operating Cash Flow | $2M | 37/55 |
| Free Cash Flow | -$2M | 28/50 |
| Capital Spending | -$4M | 13/50 |
| OCF Growth YoY | -57.7% | 31/33 |
| FCF Growth YoY | -153.4% | 23/25 |
| Metric | CERS | Rank |
|---|---|---|
| Operating Income | -$2M | 27/55 |
| Net Income | -$7M | 22/44 |
| R&D Expense | $61M | 28/53 |
| SG&A Expense | $82M | 46/53 |
| Metric | CERS | Rank |
|---|---|---|
| Shares Outstanding | 202M | – |
| Total Current Assets | $157M | 76.7% of assets |
| Cash & Short-term Investments | $18M | 8.8% of assets |
| Accounts Receivable | $31M | 15.1% of assets |
| Inventory | $66M | 32.1% of assets |
| Total Liabilities | $134M | 65.5% of assets |
| Short-term Debt | $52M | 25.5% of assets |
Companies classified under the same SEC industry code as Cerus Corp (Surgical & Medical Instruments & Apparatus): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| CERS Cerus Corp | ▲ | $439M |
| SYK Stryker Corp | ▼ | $112.48B |
| MMM 3m Co | ▶ | $84.97B |
| BSX Boston Scientific Corp | ▼ | $64.33B |
| BDX Becton Dickinson & Co | ▼ | $52.23B |
| MDLN Medline Inc. | ▶ | $47.28B |
| RMD Resmed Inc | ▼ | $34.94B |
| DXCM Dexcom Inc | ▼ | $32.47B |
| WST West Pharmaceutical Services Inc | ▼ | $26.96B |
| SOLV Solventum Corp | ▼ | $14.96B |
| BAX Baxter International Inc | ▼ | $13.07B |
| PEN Penumbra Inc | ▼ | $12.65B |
| GMED Globus Medical Inc | ▼ | $10.30B |
| GKOS Glaukos Corp | ▲ | $9.72B |
| PODD Insulet Corp | ▼ | $9.62B |
| TFX Teleflex Inc | ▼ | $5.43B |
| HAE Haemonetics Corp | ▶ | $5.38B |
| MMSI Merit Medical Systems Inc | ▼ | $5.33B |
| STVN Stevanato Group S.P.A. | ▲ | $5.26B |
| MMED Minimed Group, Inc. | ▲ | $4.92B |
| HTFL Heartflow, Inc. | ▲ | $4.20B |
| ICUI Icu Medical Inc/De | ▼ | $4.08B |
| IRTC Irhythm Holdings, Inc. | ▼ | $3.58B |
| PLSE Pulse Biosciences, Inc. | ▲ | $3.25B |
| ATRC Atricure, Inc. | ▲ | $2.85B |
| UFPT Ufp Technologies Inc | ▼ | $2.30B |
| INSP Inspire Medical Systems, Inc. | ▲ | $1.99B |
| LMAT Lemaitre Vascular Inc | ▶ | $1.85B |
| NVCR Novocure Ltd | ▲ | $1.68B |
| KMTS Kestra Medical Technologies, Ltd. | ▲ | $1.62B |
| ATEC Alphatec Holdings, Inc. | ▲ | $1.62B |
| DRTS Alpha Tau Medical Ltd. | ▶ | $1.16B |
| TNDM Tandem Diabetes Care Inc | ▲ | $1.15B |
| IRMD Iradimed Corp | ▶ | $1.13B |
| AORT Artivion, Inc. | ▶ | $1.06B |
| PRCT Procept Biorobotics Corp | ▲ | $1.04B |
| IART Integra Lifesciences Holdings Corp | ▶ | $1.03B |
| BVS Bioventus Inc. | ▶ | $908M |
| SIBN Si-Bone, Inc. | ▶ | $892M |
| BBNX Beta Bionics, Inc. | ▲ | $863M |
| SGP Spyglass Pharma, Inc. | ▲ | $827M |
| MDXG Mimedx Group, Inc. | ▶ | $682M |
| KIDS Orthopediatrics Corp | ▶ | $573M |
| TCMD Tactile Systems Technology Inc | ▼ | $528M |
| SSII Ss Innovations International, Inc. | ▲ | $517M |
| DCTH Delcath Systems, Inc. | ▲ | $497M |
| SGHT Sight Sciences, Inc. | ▲ | $485M |
| ANGO Angiodynamics Inc | ▲ | $473M |
| BWAY Brainsway Ltd. | ▶ | $448M |
| NPCE Neuropace Inc | ▲ | $420M |
| RCEL Avita Medical, Inc. | ▲ | $415M |
| OFIX Orthofix Medical Inc. | ▼ | $391M |
| CARL Carlsmed, Inc. | ▲ | $366M |
| EMBC Embecta Corp. | ▶ | $355M |
| OBIO Orchestra Biomed Holdings, Inc. | ▲ | $345M |
| CLPT Clearpoint Neuro, Inc. | ▲ | $277M |
| MOBI Mobia Medical, Inc. | ▼ | $269M |
| TMCI Treace Medical Concepts, Inc. | ▲ | $268M |
| ANIK Anika Therapeutics, Inc. | ▶ | $267M |
| OSUR Orasure Technologies Inc | ▲ | $263M |
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Cerus Corp, known for its blood safety systems, operates in a demanding healthcare environment where regulatory expectations, hospital budgets and innovation cycles intersect. For investors, the ...
Our AI ranks Cerus Corp outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
For CERS, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 29.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 25.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Cerus Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
60 issuers in our coverage, CERS included, share the SEC industry code Surgical & Medical Instruments & Apparatus. The largest are: Stryker Corp (SYK), 3m Co (MMM), Boston Scientific Corp (BSX), Becton Dickinson & Co (BDX), Medline Inc. (MDLN), Resmed Inc (RMD).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.